{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:39:38Z","timestamp":1794746378200,"version":"4.9.1"},"reference-count":71,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"unspecified","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019959","name":"Inozyme Pharma","doi-asserted-by":"publisher","award":["None"],"award-info":[{"award-number":["None"]}],"id":[{"id":"10.13039\/100019959","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Rady Children\u2019s Hospital","id":[{"id":"https:\/\/ror.org\/0511k4970","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007560","name":"Chiesi Farmaceutici","doi-asserted-by":"publisher","award":["None"],"award-info":[{"award-number":["None"]}],"id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Rady Children\u2019s Institute for Genomic Medicine","id":[{"id":"https:\/\/ror.org\/01v97x551","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals","doi-asserted-by":"publisher","award":["None"],"award-info":[{"award-number":["None"]}],"id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["None"],"award-info":[{"award-number":["None"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Rocket Pharma","award":["None"],"award-info":[{"award-number":["None"]}]},{"DOI":"10.13039\/501100024091","name":"Orchard Therapeutics","doi-asserted-by":"publisher","award":["None"],"award-info":[{"award-number":["None"]}],"id":[{"id":"10.13039\/501100024091","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Mahzi Therapeutics","award":["None"],"award-info":[{"award-number":["None"]}]},{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","award":["None"],"award-info":[{"award-number":["None"]}],"id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1TR004407"],"award-info":[{"award-number":["UM1TR004407"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sentynyl Therapeutics","award":["None"],"award-info":[{"award-number":["None"]}]},{"DOI":"10.13039\/100014943","name":"Sarepta Therapeutics","doi-asserted-by":"publisher","award":["None"],"award-info":[{"award-number":["None"]}],"id":[{"id":"10.13039\/100014943","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013220","name":"Ultragenyx Pharmaceutical","doi-asserted-by":"publisher","award":["None"],"award-info":[{"award-number":["None"]}],"id":[{"id":"10.13039\/100013220","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical","doi-asserted-by":"publisher","award":["None"],"award-info":[{"award-number":["None"]}],"id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","award":["None"],"award-info":[{"award-number":["None"]}],"id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Travere Therapeutics","award":["None"],"award-info":[{"award-number":["None"]}],"id":[{"id":"https:\/\/ror.org\/05x5gq702","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,10,20]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>In the last 60 years, newborn bloodspot screening (NBS) has expanded as a public health intervention from a single severe childhood genetic disease (SCGD) to up to as many as 80 SCGD and testing of ~40\u2009million newborns\/year worldwide. However, the gap between current NBS and its potential to increase the efficiency, effectiveness and global equity of healthcare delivery for SCGD is large and rapidly growing. There are now effective therapeutic interventions\u2014drugs, diets, devices and surgeries\u2014for up to 2000 SCGD. Since almost all SCGD can be identified by bloodspot genome sequencing, it has been a longstanding goal to supplement current NBS with genome sequencing-based NBS (gNBS) for all eligible SCGD. We recently described a novel gNBS platform (named Begin Newborn Genome Sequencing (BeginNGS)) with the potential to overcome several major challenges to gNBS (cost, scalability, false positives and an unprepared healthcare workforce). A pilot clinical trial of BeginNGS for 412 SCGD in a level IV neonatal intensive care unit (NICU) had a true positive rate of 4.2%, sensitivity of 83%, positive predictive value of 100% and clinical utility rate of 4.2%, indicating readiness of the platform for use in a powered, multicentre study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>The BeginNGS study is a single group, international, multicentre, adaptive clinical trial to compare utility, acceptability, feasibility and cost-effectiveness of BeginNGS gNBS (experimental intervention) with standard NBS (control). A minimum of 10\u2009000 neonates (aged &lt;28\u2009days, maximum of 100 000) will be enrolled across 25 racial, ethnic and ancestry populations and five enrolment site types (high-risk obstetrician offices, labour induction office visits, newborn nurseries, NICUs and well-baby visits). BeginNGS is gNBS for circa 2000 SCGD (currently 508 SCGD). The primary objective of the trial is to generate equitable evidence to support broad implementation of gNBS. Enrolled newborns receive both interventions (BeginNGS and standard of care NBS). Newborns who screen positive receive confirmatory testing and medical follow-up for at least 1 year to obtain outcomes data. The primary outcome measure is clinical utility, defined as the proportion of diagnoses identified by BeginNGS and state NBS during infancy that are likely to benefit (likely to have an improved outcome) from treatment. We hypothesise that BeginNGS has a greater rate of clinical utility than standard NBS. An adaptive design was chosen rather than a traditional, fixed design to allow accumulating results to make the trial more efficient, informative, equitable and ethical by addition or removal of SCGD and genetic variants, population enrichment (for under-represented racial, ethnic and ancestral groups) and sample size re-estimation. Adaptive design will also facilitate meta-analysis with other clinical trials of gNBS, providing greater power to test utility in ultra-rare SCGD. Parents will be approached (in person, via phone or via electronic communication) to provide informed consent to enrol their newborns prenatally, postnatally in newborn nurseries or NICUs or at well baby outpatient visits. This study is part of phase III of the BeginNGS programme. Patient and public voices have been engaged in the design and execution of each BeginNGS phase through individuals and groups joining the BeginNGS consortium and participating in the family and community engagement work group. gNBS has the potential to transform the way we diagnose and treat childhood genetic diseases. Preliminary data suggest that national adoption of BeginNGS for all births has the potential to improve outcomes of &gt;50\u2009000 US children per year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This study was approved by the WCG Clinical institutional review board on 14 February 2024, and the most recent amendment approved on 7 October 2025 (approval number 20235517). Study findings will be shared through research consortium workshops, national and international conferences, community presentations and peer-reviewed journals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06306521\">NCT06306521<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-098609","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T06:25:18Z","timestamp":1763101518000},"page":"e098609","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Clinical utility and cost-effectiveness of BeginNGS newborn screening by genome sequencing and standard newborn screening for severe childhood genetic diseases: an adaptive, international and comparative clinical trial"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct06306521","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06306521","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Rebecca","family":"Reimers","sequence":"first","affiliation":[{"name":"Rady Children\u2019s Institute for Genomic Medicine, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda","family":"Bailey","sequence":"additional","affiliation":[{"name":"Rocket Pharmaceuticals, Cranbury, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chester","family":"Brown","sequence":"additional","affiliation":[{"name":"The University of Tennessee Health Science Center College of Medicine Memphis, Memphis, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kee","family":"Chan","sequence":"additional","affiliation":[{"name":"ValueMinded LLC, Milwaukee, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Defay","sequence":"additional","affiliation":[{"name":"Alexion Pharmaceuticals Inc, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terri","family":"Finkel","sequence":"additional","affiliation":[{"name":"The University of Tennessee Health Science Center College of Medicine Memphis, Memphis, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Kahn","sequence":"additional","affiliation":[{"name":"Rady Children\u2019s Institute for Genomic Medicine, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liana","family":"Protopsaltis","sequence":"additional","affiliation":[{"name":"Rady Children\u2019s Institute for Genomic Medicine, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Stoddard","sequence":"additional","affiliation":[{"name":"Rady Children\u2019s Institute for Genomic Medicine, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay J","family":"Talati","sequence":"additional","affiliation":[{"name":"The University of Tennessee Health Science Center College of Medicine Memphis, Memphis, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Wigby","sequence":"additional","affiliation":[{"name":"Rady Children\u2019s Institute for Genomic Medicine, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammira Sarah Al-Shabeeb","family":"Akil","sequence":"additional","affiliation":[{"name":"Sidra Medicine, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Wright","sequence":"additional","affiliation":[{"name":"Rady Children\u2019s Institute for Genomic Medicine, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7180-2527","authenticated-orcid":false,"given":"Stephen F","family":"Kingsmore","sequence":"additional","affiliation":[{"name":"Rady Children\u2019s Institute for Genomic Medicine, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"2026111421173328000_15.11.e098609.1","unstructured":"Wilson JMG , Jungner G , World Health Organization . Principles and Practice of Screening for Disease. World Health Organization, 1968."},{"key":"2026111421173328000_15.11.e098609.2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.14336","article-title":"Principles of Genomic Newborn Screening Programs: A Systematic Review","volume":"4","author":"Downie","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026111421173328000_15.11.e098609.3","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10132784","article-title":"Outcomes of Universal Newborn Screening Programs: Systematic Review","volume":"10","author":"Yoshinaga-Itano","year":"2021","journal-title":"J Clin Med"},{"key":"2026111421173328000_15.11.e098609.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clp.2015.03.002"},{"key":"2026111421173328000_15.11.e098609.5","doi-asserted-by":"publisher","DOI":"10.1542\/peds.32.3.338"},{"key":"2026111421173328000_15.11.e098609.6","first-page":"331","article-title":"BLOOD PHENYLALANINE LEVELS OF NEWBORN INFANTS. A ROUTINE SCREENING PROGRAM FOR THE HOSPITAL NEWBORN NURSERY","volume":"101","author":"NOTRICASIN","year":"1964","journal-title":"Calif Med"},{"key":"2026111421173328000_15.11.e098609.7","first-page":"S383","article-title":"Newborn Screening: A blueprint for the future","volume":"106","year":"2000","journal-title":"Pediatrics"},{"key":"2026111421173328000_15.11.e098609.8","first-page":"S296","article-title":"Newborn Screening: Toward a Uniform Screening Panel and System\u2014Executive Summary","volume":"117","author":"Watson","year":"2006","journal-title":"Genet Med"},{"key":"2026111421173328000_15.11.e098609.9","doi-asserted-by":"publisher","DOI":"10.1053\/j.semperi.2015.03.002"},{"key":"2026111421173328000_15.11.e098609.10","first-page":"619","article-title":"Ten great public health achievements--United States, 2001-2010","volume":"60","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026111421173328000_15.11.e098609.11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/ijns9020020","article-title":"Implementation of Newborn Screening for Conditions in the United States First Recommended during 2010\u20132018","volume":"9","author":"Singh","year":"2023","journal-title":"IJNS"},{"key":"2026111421173328000_15.11.e098609.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2024.101290"},{"key":"2026111421173328000_15.11.e098609.13","doi-asserted-by":"crossref","unstructured":"Minten T , Gold NB , Bick S , et al . Determining the characteristics of genetic disorders that predict inclusion in newborn genomic sequencing programs. medRxiv 2024. doi:10.1101\/2024.03.24.24304797","DOI":"10.1101\/2024.03.24.24304797"},{"key":"2026111421173328000_15.11.e098609.14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41573-019-0049-9","article-title":"Therapies for rare diseases: therapeutic modalities, progress and challenges ahead","volume":"19","author":"Tambuyzer","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"2026111421173328000_15.11.e098609.15","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ajmg.c.31874","article-title":"An online compendium of treatable genetic disorders","volume":"187","author":"Bick","year":"2021","journal-title":"American J of Med Genetics Pt C"},{"key":"2026111421173328000_15.11.e098609.16","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-31446-6","article-title":"An automated 13.5\u2009hour system for scalable diagnosis and acute management guidance for genetic diseases","volume":"13","author":"Owen","year":"2022","journal-title":"Nat Commun"},{"key":"2026111421173328000_15.11.e098609.17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18103\/mra.v11i10.4528","article-title":"Genome-to-Treatment and Begin Newborn Genomic Screening: A Review of System Guides for the Acute Management and Newborn Screening Follow-up of Genetic Disorders in Infants and Children","volume":"11","author":"Smith","year":"2023","journal-title":"MRAJ"},{"key":"2026111421173328000_15.11.e098609.18","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2016.193"},{"key":"2026111421173328000_15.11.e098609.19","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jpeds.2018.12.027","article-title":"An Age-Based Framework for Evaluating Genome-Scale Sequencing Results in Newborn Screening","volume":"209","author":"Milko","year":"2019","journal-title":"J Pediatr"},{"key":"2026111421173328000_15.11.e098609.20","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13073-021-00867-1","article-title":"Actionability of commercial laboratory sequencing panels for newborn screening and the importance of transparency for parental decision-making","volume":"13","author":"DeCristo","year":"2021","journal-title":"Genome Med"},{"key":"2026111421173328000_15.11.e098609.21","doi-asserted-by":"crossref","DOI":"10.1038\/s41525-024-00404-0","article-title":"Rapid genomic sequencing for genetic disease diagnosis and therapy in intensive care units: a review","volume":"9","author":"Kingsmore","year":"2024","journal-title":"NPJ Genom Med"},{"key":"2026111421173328000_15.11.e098609.22","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-genom-120921-103442"},{"key":"2026111421173328000_15.11.e098609.23","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2005-2633O"},{"key":"2026111421173328000_15.11.e098609.24","unstructured":"Collins FS . The language of life: dna and the revolution in personalized medicine 2010 (harper). 2010."},{"key":"2026111421173328000_15.11.e098609.25","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1748-720X.2010.00522.x","article-title":"Currents in contemporary ethics. State run newborn screening in the genomic era, or how to avoid drowning when drinking from a fire hose","volume":"38","author":"Clayton","year":"2010","journal-title":"J Law Med Ethics"},{"key":"2026111421173328000_15.11.e098609.26","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2014.117"},{"key":"2026111421173328000_15.11.e098609.27","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2015.111"},{"key":"2026111421173328000_15.11.e098609.28","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2018-1099C"},{"key":"2026111421173328000_15.11.e098609.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2020.08.001"},{"key":"2026111421173328000_15.11.e098609.30","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0966-5"},{"key":"2026111421173328000_15.11.e098609.31","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-023-00621-w"},{"key":"2026111421173328000_15.11.e098609.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2022.08.003"},{"key":"2026111421173328000_15.11.e098609.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2024.10.021"},{"key":"2026111421173328000_15.11.e098609.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2024.10.020"},{"key":"2026111421173328000_15.11.e098609.35","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.843","article-title":"A pilot study of assessing whole genome sequencing in newborn screening in unselected children in China","volume":"12","author":"Jian","year":"2022","journal-title":"Clin Transl Med"},{"key":"2026111421173328000_15.11.e098609.36","doi-asserted-by":"crossref","first-page":"883617","DOI":"10.3389\/fgene.2022.883617","article-title":"Utility of Whole Genome Sequencing for Population Screening of Deafness-Related Genetic Variants and Cytomegalovirus Infection in Newborns","volume":"13","author":"Xiang","year":"2022","journal-title":"Front Genet"},{"key":"2026111421173328000_15.11.e098609.37","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.866168","article-title":"Developing a National Newborn Genomes Program: An Approach Driven by Ethics, Engagement and Co-design","volume":"13","author":"Pichini","year":"2022","journal-title":"Front Genet"},{"key":"2026111421173328000_15.11.e098609.38","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41431-023-01311-1","article-title":"Expanding the Australian Newborn Blood Spot Screening Program using genomic sequencing: do we want it and are we ready?","volume":"31","author":"White","year":"2023","journal-title":"Eur J Hum Genet"},{"key":"2026111421173328000_15.11.e098609.39","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1007\/s00103-023-03777-2","article-title":"Genomic newborn screening-research approaches, challenges, and opportunities","volume":"66","author":"Brennenstuhl","year":"2023","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"2026111421173328000_15.11.e098609.40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0293503","article-title":"Genetic newborn screening and digital technologies: A project protocol based on a dual approach to shorten the rare diseases diagnostic path in Europe","volume":"18","author":"Garnier","year":"2023","journal-title":"PLoS One"},{"key":"2026111421173328000_15.11.e098609.41","doi-asserted-by":"crossref","DOI":"10.3390\/ijns10010020","article-title":"Future of Dutch NGS-Based Newborn Screening: Exploring the Technical Possibilities and Assessment of a Variant Classification Strategy","volume":"10","author":"Kiewiet","year":"2024","journal-title":"Int J Neonatal Screen"},{"key":"2026111421173328000_15.11.e098609.42","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-081426","article-title":"Prospective cohort study of genomic newborn screening: BabyScreen+ pilot study protocol","volume":"14","author":"Lunke","year":"2024","journal-title":"BMJ Open"},{"key":"2026111421173328000_15.11.e098609.43","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.31162","article-title":"Genomic Sequencing as a First-Tier Screening Test and Outcomes of Newborn Screening","volume":"6","author":"Chen","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026111421173328000_15.11.e098609.44","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1001\/jama.2024.27289","article-title":"Newborn Screening Using Genome Sequencing for Early Actionable Conditions\u2014Reply","volume":"333","author":"Ziegler","year":"2025","journal-title":"JAMA"},{"key":"2026111421173328000_15.11.e098609.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2024.08.011"},{"key":"2026111421173328000_15.11.e098609.46","doi-asserted-by":"publisher","DOI":"10.3310\/PLRQ4216"},{"key":"2026111421173328000_15.11.e098609.47","doi-asserted-by":"crossref","DOI":"10.1016\/j.socscimed.2022.115428","article-title":"Benefits and harms adopted by health economic assessments evaluating antenatal and newborn screening programmes in OECD countries: A systematic review of 336 articles and reports","volume":"314","author":"Png","year":"2022","journal-title":"Soc Sci Med"},{"key":"2026111421173328000_15.11.e098609.48","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.317.7154.307"},{"key":"2026111421173328000_15.11.e098609.49","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2013.98"},{"key":"2026111421173328000_15.11.e098609.50","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-0004.2000.580505.x"},{"key":"2026111421173328000_15.11.e098609.51","unstructured":"WHO . Guidance for Human Genome Data Collection, Access, Use and Sharing. Geneva: World Health Organization, 2024."},{"key":"2026111421173328000_15.11.e098609.52","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/s41588-024-01711-z","article-title":"Advancing genomics to improve health equity","volume":"56","author":"Madden","year":"2024","journal-title":"Nat Genet"},{"key":"2026111421173328000_15.11.e098609.53","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.154.7.714"},{"key":"2026111421173328000_15.11.e098609.54","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2014.62"},{"key":"2026111421173328000_15.11.e098609.55","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/ajmg.c.32005","article-title":"Dispatches from Biotech beginning BeginNGS: Rapid newborn genome sequencing to end the diagnostic and therapeutic odyssey","volume":"190","author":"Kingsmore","year":"2022","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"2026111421173328000_15.11.e098609.56","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1017-7"},{"key":"2026111421173328000_15.11.e098609.57","unstructured":"Generation study protocol. Version 4.0, Available: https:\/\/files.genomicsengland.co.uk\/images\/Generation-Study-Protocol-V4.0.pdf [Accessed 22 Nov 2024]."},{"key":"2026111421173328000_15.11.e098609.58","doi-asserted-by":"publisher","DOI":"10.1177\/070674370805300408"},{"key":"2026111421173328000_15.11.e098609.59","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2021-326344"},{"key":"2026111421173328000_15.11.e098609.60","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3390\/ijns8030044","article-title":"Economic Evaluation of Newborn Screening for Severe Combined Immunodeficiency","volume":"8","author":"Shih","year":"2022","journal-title":"IJNS"},{"key":"2026111421173328000_15.11.e098609.61","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jval.2012.02.007","article-title":"Cost-effectiveness of expanded newborn screening in Texas","volume":"15","author":"Tiwana","year":"2012","journal-title":"Value Health"},{"key":"2026111421173328000_15.11.e098609.62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2011.07.007"},{"key":"2026111421173328000_15.11.e098609.63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2020.07.033"},{"key":"2026111421173328000_15.11.e098609.64","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1172-8-167","article-title":"Newborn screening by tandem mass spectrometry for glutaric aciduria type 1: a cost-effectiveness analysis","volume":"8","author":"Pfeil","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"2026111421173328000_15.11.e098609.65","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.21022"},{"key":"2026111421173328000_15.11.e098609.66","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.879"},{"key":"2026111421173328000_15.11.e098609.67","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003862","article-title":"Analysis of East Asia Genetic Substructure Using Genome-Wide SNP Arrays","volume":"3","author":"Tian","year":"2008","journal-title":"PLoS ONE"},{"key":"2026111421173328000_15.11.e098609.68","doi-asserted-by":"crossref","DOI":"10.1186\/s41065-018-0057-5","article-title":"Genetic structure, divergence and admixture of Han Chinese, Japanese and Korean populations","volume":"155","author":"Wang","year":"2018","journal-title":"Hereditas"},{"key":"2026111421173328000_15.11.e098609.69","doi-asserted-by":"publisher","DOI":"10.1038\/nature15393"},{"key":"2026111421173328000_15.11.e098609.70","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.08.004"},{"key":"2026111421173328000_15.11.e098609.71","unstructured":"US Preventive Services Task Force Procedure Manual . US Preventive Services Task Force, 2021. Available: https:\/\/uspreventiveservicestaskforce.org\/uspstf\/about-uspstf\/methods-and-processes\/procedure-manual"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-098609","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T05:20:19Z","timestamp":1794720019000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-098609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":71,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,13]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/bmjopen-2024-098609"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-098609","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bmjopen-2024-098609.supp1","asserted-by":"subject"}]},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}